Details:
Jyseleca (filgotinib) inhibits the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and some other conditions.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
Filgotinib is marketed as Jyseleca (200mg and 100mg tablets) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs).
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The study showed that Jyseleca 200mg was well-tolerated and efficacious as induction and maintenance therapy with no new safety findings reported. The approval of Jyseleca in Japan is based on data from phase 2b/3 SELECTION study in patients with ulcerative colitis.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Filgotinib is licensed and marketed as Jyseleca (200mg and 100mg tablets) in Great Britain, the European Union and Japan for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately or are intolerant.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
The European Commission approved an additional indication for Jyseleca, an oral, once-daily, JAK1 preferential inhibitor, for adult patients with moderately to severely active UC based on data from the Phase 2b/3 SELECTION program.
Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: Jyseleca
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021